Table 1.
Patient and treatment characteristics.
| Characteristics | % | |
|---|---|---|
| Sex | n | |
| male | 24 | 55% |
| female | 20 | 45% |
| Age at diagnosis | years | |
| Median | 2,6 | |
| Min | 0.1 | |
| Max | 8.7 | |
| Age at start of proton therapy | years | |
| Median | 3.4 | |
| Min | 1.4 | |
| Max | 9.9 | |
| Risk grouping | n | |
| high | 39 | 89% |
| intermediate | 5 | 11% |
| nMYC Status | n | |
| amplified | 29 | 66% |
| non-amplified | 15 | 34% |
| Induction chemotherapy | n | |
| yes | 44 | 100% |
| no | 0 | 0% |
| Resection status | n | |
| CME | 13 | 30% |
| IME | 30 | 68% |
| none | 1 | 2% |
| High-dose chemotherapy | n | |
| none | 5 | 11% |
| BuMel | 32 | 73% |
| MEC | 6 | 14% |
| TreoMel | 1 | 2% |
| Radiotherapy treatment concept | n | |
| 36–39.6 Gy to residue | 4 | 9% |
| 21.6 Gy to preop.TU; boost to residue to cum. 36 Gy | 33 | 75% |
| 21 Gy to preop. TU | 7 | 16% |
| Median total PBT dose | Gy | |
| 36.0 | ||
| Median number of fractions | n | |
| 20 | ||
| Consolidation therapy | n | |
| immunotherapy | 36 | 82% |
| retino acid | 5 | 11% |
| none | 3 | 18% |
n, number; GPOH regime, German Society for Paediatric Oncology and Hematology (GPOH) regimen [three N5 (cisplatin, etoposide, and vindesine) and three N6 cycles (vincristine, dacarbacine, ifosfamide, and doxorubicine)], Rapid Cojek (cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide with subsequent administration of Granulocyte Colony Stimulating Factor); CME, Complete macroscopic excision; IME, Incomplete macroscopic excision; BuMel, Busulphan and Melphalan; MEC, Melphalan, Etoposide, and Carboplatin; TreoMel, treosulfan–melphalan.